Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales
This article was originally published in The Tan Sheet
Executive Summary
Significantly lower sales of GlaxoSmithKline's alli OTC weight-loss drug combined with struggles in the nicotine replacement therapy category weighed down the consumer health care division's performance in the firm's latest quarter